PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer

Novel drugs like Abiraterone or Enzalutamide, which target androgen receptor (AR) signaling to improve androgen deprivation therapy (ADT), have been developed during the past years. However, the application of these drugs is limited because of occurrence of inherent or acquired therapy resistances d...

Descripción completa

Detalles Bibliográficos
Autores principales: Puhr, M, Hoefer, J, Eigentler, A, Dietrich, D, van Leenders, G, Uhl, B, Hoogland, M, Handle, F, Schlick, B, Neuwirt, H, Sailer, V, Kristiansen, G, Klocker, H, Culig, Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865476/
https://www.ncbi.nlm.nih.gov/pubmed/26257066
http://dx.doi.org/10.1038/onc.2015.292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865476/
https://www.ncbi.nlm.nih.gov/pubmed/26257066
http://dx.doi.org/10.1038/onc.2015.292

Ejemplares similares